Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box 3 pseudogene 17 (HMGB3P17) is a transcribed human pseudogene representing a nonfunctional variant of the high mobility group box 3 gene. Pseudogenes are DNA sequences similar to functional genes but lack the ability to encode proteins due to mutations accumulated over evolution, including promoter loss, frameshift mutations, or premature stop codons[5][8][9]. HMGB3P17 may be transcribed under certain conditions and could participate in post-transcriptional gene regulation, such as acting as an RNA scaffold in developmental contexts or modulating RNA stability by competing for microRNAs or RNA-binding proteins[2][5]. It is not considered a conventional therapeutic target, nor are there described drugs, mechanisms, biomarkers, or safety concerns directly associated with this gene. Pseudogenes in general may be misannotated in large-scale genetic studies or complicate molecular diagnostics due to their sequence similarity to functional relatives[8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 3 pseudogene 17 (HMGB3P17).